---
title: "Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287775165.md"
description: "The market for wet age-related macular degeneration (AMD) is forecasted to expand as the number of diagnosed cases continues to rise. This growth is further fueled by the introduction of new therapies like Ixoberogene soroparvovec (Ixo-vec) by Adverum Biotechnologies, Surabgene lomparvovec (RGX-314) by Regenxbio/AbbVie, and OGX-110. These emerging treatments are expected to contribute to the market’s upward trajectory alongside current therapies."
datetime: "2026-05-27T12:36:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287775165.md)
  - [en](https://longbridge.com/en/news/287775165.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287775165.md)
---

# Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight

The market for wet age-related macular degeneration (AMD) is forecasted to expand as the number of diagnosed cases continues to rise. This growth is further fueled by the introduction of new therapies like Ixoberogene soroparvovec (Ixo-vec) by Adverum Biotechnologies, Surabgene lomparvovec (RGX-314) by Regenxbio/AbbVie, and OGX-110. These emerging treatments are expected to contribute to the market’s upward trajectory alongside current therapies.

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [ADVM.US](https://longbridge.com/en/quote/ADVM.US.md)
- [RGNX.US](https://longbridge.com/en/quote/RGNX.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [AbbVie Inc Stock (ABBV) Moved Up by 3.35% on Jul 28: A Full Analysis](https://longbridge.com/en/news/294086753.md)
- [The Bull Case For AbbVie (ABBV) Could Change Following EU Approval Of Rinvoq For Vitiligo](https://longbridge.com/en/news/294200563.md)
- [REGENXBIO (RGNX) Projected to Post Earnings on Thursday](https://longbridge.com/en/news/294335262.md)
- [Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments](https://longbridge.com/en/news/293231242.md)
- [Regenxbio reports 5-year wet AMD efficacy data for sura-vec gene therapy at ASRS meeting](https://longbridge.com/en/news/293104812.md)